A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
List view / Grid view
Acute lymphoblastic leukaemia
Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
A new study into the molecular causes of acute lymphoblastic leukaemia could lead to a new target for therapy.
Scientists in the US have developed a promising new CAR T-cell therapy that targets the BAFF-R protein, which has demonstrated superior cancer destruction to existing FDA-approved CAR-T therapies.
Researchers have discovered a new combination therapy to treat drug-resistant acute lymphoblastic leukaemia, tested in pre-clinical trials.
A single leukemic cell has become resistant to CAR-T therapy after unknowingly engineered with the leukemia-targeting CAR lentivirus...
Enzyme therapy is a promising form of cancer treatment. The specific nature of enzyme and substrate interaction gives enzyme therapy an edge compared to standard non-specific therapies such as radiation and chemotherapy. However, since most of these enzymes are of a foreign nature, the delivery of these immunogenic enzymes has…